Potentiation of anti-angiogenic activity of heparin by blocking the ATIII-interacting pentasaccharide unit and increasing net anionic charge

Seung Woo Chung, Myungjin Lee, Sang Mun Bae, Jooho Park, Ok Cheol Jeon, Hui Sun Lee, Han Choe, Han Sung Kim, Beom Suk Lee, Rang Woon Park, Sang Yoon Kim, Youngro Byun

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Heparin, a potent anticoagulant used for the prevention of venous thromboembolism, has been recognized as a tumor angiogenesis inhibitor. Its limitation in clinical application for cancer therapy, however, arises from its strong anticoagulant activity, which causes associated adverse effects. In this study, we show the structural correlation of LHT7, a previously developed heparin-based angiogenesis inhibitor, with its influence on VEGF blockade and its decreased anticoagulant activity. LHT7 was characterized as having average seven molecules of sodium taurocholates conjugated to one molecule of low-molecular-weight heparin (LMWH). This study showed that the conjugation of sodium taurocholates selectively blocked interaction with antithrombin III (ATIII) while enhancing the binding with VEGF. This resulted in LHT7 to have negligible anticoagulant activity but potent anti-angiogenic activity. Following up on this finding, we showed that the bidirectional effect of sodium taurocholate conjugation was due to its unique structure, that is, the sterane core hindering the ATIII-binding pentasaccharide unit of LMWH with its bulky and rigid structural characteristics while the terminal sulfate group interacts with VEGF to produce stronger binding. In addition, we showed that LHT7 was localized in the tumor, especially on the endothelial cells. One explanation for this might be that LHT7 was delivered to the tumor via platelets.

Original languageEnglish
Pages (from-to)9070-9079
Number of pages10
JournalBiomaterials
Volume33
Issue number35
DOIs
Publication statusPublished - 2012 Dec 1

Fingerprint

Antithrombin III
Anticoagulants
Taurocholic Acid
Heparin
Vascular Endothelial Growth Factor A
Tumors
Angiogenesis Inhibitors
Low Molecular Weight Heparin
Sodium
Neoplasms
Molecular weight
Molecules
Venous Thromboembolism
Endothelial cells
Platelets
Sulfates
Blood Platelets
Endothelial Cells
Therapeutics

All Science Journal Classification (ASJC) codes

  • Bioengineering
  • Ceramics and Composites
  • Biophysics
  • Biomaterials
  • Mechanics of Materials

Cite this

Chung, Seung Woo ; Lee, Myungjin ; Bae, Sang Mun ; Park, Jooho ; Jeon, Ok Cheol ; Lee, Hui Sun ; Choe, Han ; Kim, Han Sung ; Lee, Beom Suk ; Park, Rang Woon ; Kim, Sang Yoon ; Byun, Youngro. / Potentiation of anti-angiogenic activity of heparin by blocking the ATIII-interacting pentasaccharide unit and increasing net anionic charge. In: Biomaterials. 2012 ; Vol. 33, No. 35. pp. 9070-9079.
@article{3556e0c457da4a57b9368e86b05a384f,
title = "Potentiation of anti-angiogenic activity of heparin by blocking the ATIII-interacting pentasaccharide unit and increasing net anionic charge",
abstract = "Heparin, a potent anticoagulant used for the prevention of venous thromboembolism, has been recognized as a tumor angiogenesis inhibitor. Its limitation in clinical application for cancer therapy, however, arises from its strong anticoagulant activity, which causes associated adverse effects. In this study, we show the structural correlation of LHT7, a previously developed heparin-based angiogenesis inhibitor, with its influence on VEGF blockade and its decreased anticoagulant activity. LHT7 was characterized as having average seven molecules of sodium taurocholates conjugated to one molecule of low-molecular-weight heparin (LMWH). This study showed that the conjugation of sodium taurocholates selectively blocked interaction with antithrombin III (ATIII) while enhancing the binding with VEGF. This resulted in LHT7 to have negligible anticoagulant activity but potent anti-angiogenic activity. Following up on this finding, we showed that the bidirectional effect of sodium taurocholate conjugation was due to its unique structure, that is, the sterane core hindering the ATIII-binding pentasaccharide unit of LMWH with its bulky and rigid structural characteristics while the terminal sulfate group interacts with VEGF to produce stronger binding. In addition, we showed that LHT7 was localized in the tumor, especially on the endothelial cells. One explanation for this might be that LHT7 was delivered to the tumor via platelets.",
author = "Chung, {Seung Woo} and Myungjin Lee and Bae, {Sang Mun} and Jooho Park and Jeon, {Ok Cheol} and Lee, {Hui Sun} and Han Choe and Kim, {Han Sung} and Lee, {Beom Suk} and Park, {Rang Woon} and Kim, {Sang Yoon} and Youngro Byun",
year = "2012",
month = "12",
day = "1",
doi = "10.1016/j.biomaterials.2012.09.002",
language = "English",
volume = "33",
pages = "9070--9079",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",
number = "35",

}

Chung, SW, Lee, M, Bae, SM, Park, J, Jeon, OC, Lee, HS, Choe, H, Kim, HS, Lee, BS, Park, RW, Kim, SY & Byun, Y 2012, 'Potentiation of anti-angiogenic activity of heparin by blocking the ATIII-interacting pentasaccharide unit and increasing net anionic charge', Biomaterials, vol. 33, no. 35, pp. 9070-9079. https://doi.org/10.1016/j.biomaterials.2012.09.002

Potentiation of anti-angiogenic activity of heparin by blocking the ATIII-interacting pentasaccharide unit and increasing net anionic charge. / Chung, Seung Woo; Lee, Myungjin; Bae, Sang Mun; Park, Jooho; Jeon, Ok Cheol; Lee, Hui Sun; Choe, Han; Kim, Han Sung; Lee, Beom Suk; Park, Rang Woon; Kim, Sang Yoon; Byun, Youngro.

In: Biomaterials, Vol. 33, No. 35, 01.12.2012, p. 9070-9079.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Potentiation of anti-angiogenic activity of heparin by blocking the ATIII-interacting pentasaccharide unit and increasing net anionic charge

AU - Chung, Seung Woo

AU - Lee, Myungjin

AU - Bae, Sang Mun

AU - Park, Jooho

AU - Jeon, Ok Cheol

AU - Lee, Hui Sun

AU - Choe, Han

AU - Kim, Han Sung

AU - Lee, Beom Suk

AU - Park, Rang Woon

AU - Kim, Sang Yoon

AU - Byun, Youngro

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Heparin, a potent anticoagulant used for the prevention of venous thromboembolism, has been recognized as a tumor angiogenesis inhibitor. Its limitation in clinical application for cancer therapy, however, arises from its strong anticoagulant activity, which causes associated adverse effects. In this study, we show the structural correlation of LHT7, a previously developed heparin-based angiogenesis inhibitor, with its influence on VEGF blockade and its decreased anticoagulant activity. LHT7 was characterized as having average seven molecules of sodium taurocholates conjugated to one molecule of low-molecular-weight heparin (LMWH). This study showed that the conjugation of sodium taurocholates selectively blocked interaction with antithrombin III (ATIII) while enhancing the binding with VEGF. This resulted in LHT7 to have negligible anticoagulant activity but potent anti-angiogenic activity. Following up on this finding, we showed that the bidirectional effect of sodium taurocholate conjugation was due to its unique structure, that is, the sterane core hindering the ATIII-binding pentasaccharide unit of LMWH with its bulky and rigid structural characteristics while the terminal sulfate group interacts with VEGF to produce stronger binding. In addition, we showed that LHT7 was localized in the tumor, especially on the endothelial cells. One explanation for this might be that LHT7 was delivered to the tumor via platelets.

AB - Heparin, a potent anticoagulant used for the prevention of venous thromboembolism, has been recognized as a tumor angiogenesis inhibitor. Its limitation in clinical application for cancer therapy, however, arises from its strong anticoagulant activity, which causes associated adverse effects. In this study, we show the structural correlation of LHT7, a previously developed heparin-based angiogenesis inhibitor, with its influence on VEGF blockade and its decreased anticoagulant activity. LHT7 was characterized as having average seven molecules of sodium taurocholates conjugated to one molecule of low-molecular-weight heparin (LMWH). This study showed that the conjugation of sodium taurocholates selectively blocked interaction with antithrombin III (ATIII) while enhancing the binding with VEGF. This resulted in LHT7 to have negligible anticoagulant activity but potent anti-angiogenic activity. Following up on this finding, we showed that the bidirectional effect of sodium taurocholate conjugation was due to its unique structure, that is, the sterane core hindering the ATIII-binding pentasaccharide unit of LMWH with its bulky and rigid structural characteristics while the terminal sulfate group interacts with VEGF to produce stronger binding. In addition, we showed that LHT7 was localized in the tumor, especially on the endothelial cells. One explanation for this might be that LHT7 was delivered to the tumor via platelets.

UR - http://www.scopus.com/inward/record.url?scp=84867143259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867143259&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2012.09.002

DO - 10.1016/j.biomaterials.2012.09.002

M3 - Article

C2 - 23010574

AN - SCOPUS:84867143259

VL - 33

SP - 9070

EP - 9079

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

IS - 35

ER -